SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Celldex Therapeutics, Inc. – ‘10-Q’ for 6/30/22 – ‘EX-101.SCH’

On:  Monday, 8/8/22, at 4:06pm ET   ·   For:  6/30/22   ·   Accession #:  1104659-22-87222   ·   File #:  0-15006

Previous ‘10-Q’:  ‘10-Q’ on 5/5/22 for 3/31/22   ·   Next:  ‘10-Q’ on 11/9/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 11/2/23 for 9/30/23   ·   4 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/08/22  Celldex Therapeutics, Inc.        10-Q        6/30/22   60:5.5M                                   Toppan Merrill/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.26M 
 2: EX-10.3     Material Contract                                   HTML     29K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
11: R1          Document and Entity Information                     HTML     73K 
12: R2          Condensed Consolidated Balance Sheets               HTML    113K 
13: R3          Condensed Consolidated Balance Sheets               HTML     35K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     86K 
                and Comprehensive Loss                                           
15: R5          Condensed Consolidated Statements of Cash Flow      HTML     80K 
16: R6          Basis of Presentation                               HTML     25K 
17: R7          Significant Accounting Policies                     HTML     21K 
18: R8          Fair Value Measurements                             HTML     96K 
19: R9          Marketable Securities                               HTML    110K 
20: R10         Intangible Assets                                   HTML     20K 
21: R11         Other Long-Term Liabilities                         HTML     36K 
22: R12         Stockholders' Equity                                HTML    153K 
23: R13         Stock-Based Compensation                            HTML     81K 
24: R14         Accumulated Other Comprehensive Income              HTML     40K 
25: R15         Revenue                                             HTML     23K 
26: R16         Income Taxes                                        HTML     22K 
27: R17         Net Loss Per Share                                  HTML     27K 
28: R18         Kolltan Acquisition                                 HTML     28K 
29: R19         Significant Accounting Policies (Policies)          HTML     20K 
30: R20         Fair Value Measurements (Tables)                    HTML     95K 
31: R21         Marketable Securities (Tables)                      HTML    108K 
32: R22         Other Long-Term Liabilities (Tables)                HTML     35K 
33: R23         Stockholders' Equity (Tables)                       HTML    148K 
34: R24         Stock-Based Compensation (Tables)                   HTML     84K 
35: R25         Accumulated Other Comprehensive Income (Tables)     HTML     39K 
36: R26         Net Loss Per Share (Tables)                         HTML     26K 
37: R27         Basis of Presentation (Details)                     HTML     30K 
38: R28         Fair Value Measurements (Details)                   HTML     45K 
39: R29         Fair Value Measurements - Contingent Consideration  HTML     26K 
                Liabilities (Details)                                            
40: R30         Fair Value Measurements - Additional information    HTML     29K 
                (Details)                                                        
41: R31         Marketable Securities (Details)                     HTML     58K 
42: R32         Marketable Securities - Additional Information      HTML     21K 
                (Details)                                                        
43: R33         Intangible Assets (Details)                         HTML     19K 
44: R34         Other Long-Term Liabilities (Details)               HTML     32K 
45: R35         Other Long-Term Liabilities- New Jersey tax         HTML     26K 
                benefits (Details)                                               
46: R36         Stockholders' Equity (Details)                      HTML     60K 
47: R37         Stock-Based Compensation - Stock Option Activity    HTML     64K 
                (Details)                                                        
48: R38         Stock-Based Compensation - Employee Stock Option    HTML     29K 
                and Incentive Plan Activity Additional Information               
                (Details)                                                        
49: R39         Stock-Based Compensation - Expenses (Details)       HTML     24K 
50: R40         Stock-Based Compensation - Valuation (Details)      HTML     32K 
51: R41         Accumulated Other Comprehensive Income (Details)    HTML     38K 
52: R42         Revenue (Details)                                   HTML     38K 
53: R43         Income Taxes (Details)                              HTML     19K 
54: R44         Net Loss Per Share (Details)                        HTML     22K 
55: R45         Kolltan Acquisition (Details)                       HTML     39K 
58: XML         IDEA XML File -- Filing Summary                      XML    103K 
56: XML         XBRL Instance -- cldx-20220630x10q_htm               XML   1.45M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     82K 
 7: EX-101.CAL  XBRL Calculations -- cldx-20220630_cal               XML    114K 
 8: EX-101.DEF  XBRL Definitions -- cldx-20220630_def                XML    327K 
 9: EX-101.LAB  XBRL Labels -- cldx-20220630_lab                     XML    756K 
10: EX-101.PRE  XBRL Presentations -- cldx-20220630_pre              XML    529K 
 6: EX-101.SCH  XBRL Schema -- cldx-20220630                         XSD     94K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              248±   387K 
60: ZIP         XBRL Zipped Folder -- 0001104659-22-087222-xbrl      Zip    221K

‘EX-101.SCH’   —   XBRL Schema — cldx-20220630

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 9.6.8167.22744 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 8/2/2022 9:33:26 AM -->
<!-- Modified on: 8/2/2022 9:33:26 AM -->
<xsd:schema targetNamespace="http://www.celldextherapeutics.com/20220630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:cldx="http://www.celldextherapeutics.com/20220630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
<xsd:annotation>
<xsd:appinfo>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
<link:definition> 99900 - Disclosure - Standard And Custom Axis Domain Defaults </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
<link:definition> 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition> 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow" id="StatementCondensedConsolidatedStatementsOfCashFlow">
<link:definition> 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
<link:definition> 40301 - Disclosure - Fair Value Measurements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesDetails">
<link:definition> 40401 - Disclosure - Marketable Securities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" id="DisclosureOtherLongTermLiabilitiesDetails">
<link:definition> 40601 - Disclosure - Other Long-Term Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2" id="DisclosureOtherLongTermLiabilitiesDetailsCalc2">
<link:definition> 40701 - Disclosure - Other Long-Term Liabilities (Details) (Calc 2) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition> 00090 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
<link:definition> 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
<link:definition> 40101 - Disclosure - Basis of Presentation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails" id="DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails">
<link:definition> 40302 - Disclosure - Fair Value Measurements - Contingent Consideration Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
<link:definition> 40303 - Disclosure - Fair Value Measurements - Additional information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsDetails" id="DisclosureIntangibleAssetsDetails">
<link:definition> 40501 - Disclosure - Intangible Assets (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails" id="DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails">
<link:definition> 40602 - Disclosure - Other Long-Term Liabilities- New Jersey tax benefits (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
<link:definition> 40701 - Disclosure - Stockholders' Equity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
<link:definition> 40801 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails" id="DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails">
<link:definition> 40802 - Disclosure - Stock-Based Compensation - Employee Stock Option and Incentive Plan Activity Additional Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails" id="DisclosureStockBasedCompensationExpensesDetails">
<link:definition> 40803 - Disclosure - Stock-Based Compensation - Expenses (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails" id="DisclosureStockBasedCompensationValuationDetails">
<link:definition> 40804 - Disclosure - Stock-Based Compensation - Valuation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails" id="DisclosureAccumulatedOtherComprehensiveIncomeDetails">
<link:definition> 40901 - Disclosure - Accumulated Other Comprehensive Income (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
<link:definition> 41001 - Disclosure - Revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
<link:definition> 41101 - Disclosure - Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
<link:definition> 41201 - Disclosure - Net Loss Per Share (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails" id="DisclosureKolltanAcquisitionDetails">
<link:definition> 41301 - Disclosure - Kolltan Acquisition (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
<link:definition> 10101 - Disclosure - Basis of Presentation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
<link:definition> 10201 - Disclosure - Significant Accounting Policies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
<link:definition> 10301 - Disclosure - Fair Value Measurements </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
<link:definition> 10401 - Disclosure - Marketable Securities </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
<link:definition> 10501 - Disclosure - Intangible Assets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" id="DisclosureOtherLongTermLiabilities">
<link:definition> 10601 - Disclosure - Other Long-Term Liabilities </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
<link:definition> 10701 - Disclosure - Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
<link:definition> 10801 - Disclosure - Stock-Based Compensation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncome" id="DisclosureAccumulatedOtherComprehensiveIncome">
<link:definition> 10901 - Disclosure - Accumulated Other Comprehensive Income </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenue" id="DisclosureRevenue">
<link:definition> 11001 - Disclosure - Revenue </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
<link:definition> 11101 - Disclosure - Income Taxes </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
<link:definition> 11201 - Disclosure - Net Loss Per Share </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisition" id="DisclosureKolltanAcquisition">
<link:definition> 11301 - Disclosure - Kolltan Acquisition </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
<link:definition> 20202 - Disclosure - Significant Accounting Policies (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
<link:definition> 30303 - Disclosure - Fair Value Measurements (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
<link:definition> 30403 - Disclosure - Marketable Securities (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" id="DisclosureOtherLongTermLiabilitiesTables">
<link:definition> 30603 - Disclosure - Other Long-Term Liabilities (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
<link:definition> 30703 - Disclosure - Stockholders' Equity (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
<link:definition> 30803 - Disclosure - Stock-Based Compensation (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" id="DisclosureAccumulatedOtherComprehensiveIncomeTables">
<link:definition> 30903 - Disclosure - Accumulated Other Comprehensive Income (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
<link:definition> 31203 - Disclosure - Net Loss Per Share (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
<link:definition> 40402 - Disclosure - Marketable Securities - Additional Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</xsd:appinfo>
</xsd:annotation>
<xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
<xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
<xsd:element id="cldx_DeferredIncomeFromSaleOfTaxBenefits" name="DeferredIncomeFromSaleOfTaxBenefits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="PeriodForWhichBaseOfOperationsMustBeMaintained" id="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" id="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" id="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_ProceedsFromSaleOfOperatingLossesAndTaxCredits" name="ProceedsFromSaleOfOperatingLossesAndTaxCredits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="cldx_StockIssuedRemainingAuthorizedAmount" name="StockIssuedRemainingAuthorizedAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="cldx_KolltanPharmaceuticalsMember" name="KolltanPharmaceuticalsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_ContingentMilestoneMember" name="ContingentMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="LitigationSettlementPayable" id="cldx_LitigationSettlementPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid" id="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="EuropeanMedicinesAgencyMember" id="cldx_EuropeanMedicinesAgencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable" id="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ClinicalTrailMember" id="cldx_ClinicalTrailMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement" id="cldx_BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="RockefellerUniversityAndGileadSciencesMember" id="cldx_RockefellerUniversityAndGileadSciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
</xsd:schema>

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/24  Celldex Therapeutics, Inc.        10-K       12/31/23   87:8.5M                                   Toppan Merrill/FA2
 2/28/23  Celldex Therapeutics, Inc.        10-K       12/31/22   85:8.1M                                   Toppan Merrill/FA

2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/18/22  Celldex Therapeutics, Inc.        8-K:1,9     7/15/22   11:257K                                   Toppan Merrill/FA
 6/23/22  Celldex Therapeutics, Inc.        8-K:1,2,9   6/20/22   11:225K                                   Toppan Merrill/FA
↑Top
Filing Submission 0001104659-22-087222   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., Apr. 28, 8:49:07.1am ET